Pricing Log in Create free account
Friday 6 November 2026 Export MYGN’s income statement to Excel — free account

Myriad Genetics, Inc.

MYGN Healthcare Diagnostics & Research

Myriad Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $824.5 million, down 1.56% from fiscal 2024.

Revenue
−10.5%
EPS
+87.1%
Free cash flow
+43.9%
Total debt
+103.2%

Quarter to June 2026, against a year earlier

6.19 0.17 +2.82%
Market cap
$601.6M
P/E
0.0×
Fwd P/E
−4.1×
Dividend yield
—
F-score
5/9
Altman Z
−1.52
Beneish M
−5.42
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.72
Sold, $m 0.07
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — 1 1 — 1 — — — — — —
Sell — — — — — — 1 — — — — —
Insider Ownership 6.54%

Capital & Financial Ratios $m

Size
Market Cap 601.64
Revenue ttm 806.60
Net income ttm (112.60)
Free cash flow ttm (14.20)
Net debt Q 5.50
Valuation
P/E 0.00
Forward P/E (4.05) (negative: loss-making)
Price / sales 0.73
Forward P/S Powerpack
Price / FCF 0.00
Price / book 1.93
Financial health
Current ratio Q 2.21 (at or above 1.5: strong)
Debt / equity Q 0.40 (at or below 0.5: strong)
Interest coverage Q (9.49)
Growth
Revenue growth Q −10.51% (below 0%: shrinking)
Operating income growth Q +88.18% (above 0%: growing)
EPS, this year −1,273.23% (below 0%: weak)
EPS, next year A +11.80%
Revenue, next year A −5.65% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +16.55% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.8×, against a ten-year median of 2.4×; over the ten years it ranged from 0.4× in 2026 to 4.4× in 2018.
P/S against its own 10 years 10.63%
10-year low 10-year high
P/B against its own 10 years 45.58%
10-year low 10-year high
EV/Sales against its own 10 years 11.77%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 141 102 150 115
Receivables 114 121 115 110
Inventory 22 28 31 31
Other — — — —
314 298 333 289
2023 2024 2025 Q'26
Payables 26 32 30 30
ST’ Debt — — — —
Other — — — —
156 164 134 131

Compound Annual Growth %

10y 5y 3y
Sales (0.32%) 3.61% 6.72%
Cash Flow (31.88%) (37.32%) 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (9.20%) (17.58%) (25.38%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −0.17 Actual −0.11

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 −0.02 0.04 Beat by 0.06
Q1 FY26 −0.06 −0.09 Miss by 0.03
Q2 FY26 −0.03 −0.25 Miss by 0.22
Q3 FY26 −0.17 −0.11 Beat by 0.06
Q4 FY26 −0.18 — Reports 22 February 2027

EPS $

Mar Jun Sep Dec Year
’26 (0.36) (0.46) — — —
’25 0.00 (3.57) (0.29) (0.08) (3.95)
’24 (0.29) (0.41) (0.24) (0.47) (1.41)
’23 (0.67) (1.42) (0.75) (0.36) (3.18)
’22 — — (0.43) (0.52) (1.39)
’22 (0.26) (0.18) — — (1.39)
’21 — — 0.30 (0.10) (0.35)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 200 191 — — —
’25 196 213 206 210 825
’24 202 212 213 211 838
’23 181 184 192 197 753
’22 — — 156 178 678
’22 165 179 — — 678
’21 — — 167 161 691
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (16) (8) — — —
’25 (16) (14) 21 11 2
’24 (19) 3 1 7 (9)
’23 (33) (1) (22) (55) (111)
’22 — — (3) (7) (106)
’22 (46) (50) — — (107)
’21 — — (39) (9) 19
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (22) (11) — — —
’25 (25) (20) 15 5 (26)
’24 (27) (6) 3 (8) (38)
’23 (57) (20) (40) (68) (184)
’22 — — (20) (22) (152)
’22 (53) (56) — — (107)
’21 — — (42) (13) 1
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

3.1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 741 729 744 851 639 691 678 753 838 825 807 +1.2% 778 821 871 +1.8%
Gross margin, % 78.76 76.51 76.17 76.38 70.86 71.39 70.22 68.64 69.89 69.93 68.83 (8.8) pt
EBT 156 36 120 0 (223) (57) (141) (262) (123) (395) (112) n/m
EBT margin, % 21.07 4.97 16.15 0.00 (34.97) (8.27) (20.73) (34.81) (14.74) (47.92) (13.86) (69.0) pt
Net income 117 17 133 0 0 (27) (112) (263) (127) (366) (113) n/m
Per share, $
Per share, $ Revenue 10.58 10.67 10.72 11.58 8.59 8.85 8.42 9.10 9.25 8.90 8.51 (1.9%)
Earnings 1.67 0.25 1.92 0.06 (2.69) (0.35) (1.39) (3.18) (1.41) (3.95) (1.19) n/m
Cash flow 2.38 1.55 1.67 1.14 0.82 0.24 (1.32) (1.34) (0.10) 0.02 0.08 (41.4%)
Capex (0.07) (0.09) (0.12) (0.12) (0.14) (0.23) (0.56) (0.89) (0.33) (0.30) (0.23) +17.1%
Free cash flow 2.30 1.47 1.55 1.02 0.68 0.01 (1.88) (2.22) (0.42) (0.28) (0.15) n/m
Book value 10.69 11.24 13.92 0.00 11.86 12.41 10.99 9.46 7.74 3.97 3.21 (10.4%)
Shares, m 70 68 69 74 74 78 81 83 91 93 94 +3.2%
Valuation, ×
Valuation, × P/E 19.01 80.75 18.95 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 11.9
P/S 2.93 2.41 3.54 2.49 2.30 3.12 1.81 2.09 1.48 0.69 0.73 2.3
P/B 2.90 2.26 2.72 1.88 1.67 2.22 1.39 2.01 1.77 1.55 1.93 2.0
EV/Sales 2.72 2.34 3.31 2.61 2.44 2.76 1.86 1.98 1.43 0.73 0.81 2.2
EV/FCF 8.34 13.70 15.35 25.21 30.85 3,176.67 (8.31) (8.08) (31.18) (23.41) (45.90) 319.9
Cash, $m
Cash, $m Operating cash flow 166 106 116 84 61 19 (106) (111) (9) 2 8 (39.5%)
Capex (5) (6) (8) (9) (10) (18) (45) (73) (30) (27) (22) +20.8%
Free cash flow 161 100 108 75 51 1 (152) (184) (38) (26) (14) n/m
Balance, $m
Balance, $m Working capital 242 84 225 231 244 281 137 158 134 199 158 (2.2%)
Net debt (159) (52) (171) 97 74 (339) (115) (102) (63) (30) 6 (17.0%)
Shareholders’ equity 748 768 966 1,089 881 968 886 783 701 368 304 (7.6%)
Returns, %
Returns, % ROA 14.23 1.67 11.18 0.59 (14.13) (1.99) (8.90) (22.45) (11.71) (42.20) (17.11) (56.4) pt
ROIC 16.27 3.84 9.59 0.00 (15.16) (18.93) (11.40) (23.63) (12.09) (71.53) (19.92) (87.8) pt
ROE 16.62 2.30 15.37 0.00 (22.18) (2.81) (12.64) (31.55) (17.15) (68.45) (32.54) (85.1) pt
People
People Employees 2,206 2,400 2,400 2,600 2,700 2,400 2,600 2,700 2,700 2,700 — +2.3%
Revenue/emp, $m 0.34 0.30 0.31 0.00 0.00 0.29 0.26 0.28 0.31 0.31 — (1.0%)
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 2 Nov 2026

Myriad Genetics, Inc. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
WGS GeneDx Holdings Corp. $1.9B — (loss-making) — (loss-making) +11.44% (above 0%: growing) n/m −585.59% (below 0%: shrinking) 68.37% (15.25%) Compare
PSNL Personalis, Inc. $1.7B — (loss-making) — (loss-making) +76.59% (above 0%: growing) n/m −15.54% (below 0%: shrinking) 25.67% (138.76%) Compare
OPK OPKO Health, Inc. $1.3B — (loss-making) — (loss-making) −56.87% (below 0%: shrinking) n/m −3.40% (below 0%: shrinking) 64.30% (48.02%) Compare
FRNM Freenome, Inc $1.1B — (loss-making) — — n/m +12.06% (above 0%: growing) — 0.00% Compare
CSTL Castle Biosciences, Inc. $1.0B — (loss-making) — (loss-making) +23.90% (above 0%: growing) n/m +56.82% (above 0%: growing) 76.75% (2.65%) Compare
MYGN Myriad Genetics, Inc. $601.6M — (loss-making) — (loss-making) −10.51% (below 0%: shrinking) n/m +43.90% (above 0%: growing) 66.60% (20.40%)
FLGT Fulgent Genetics, Inc. $513.4M — (loss-making) — (loss-making) +7.54% (above 0%: growing) n/m +2,058.74% (above 0%: growing) 35.33% (24.94%) Compare
BDSX Biodesix, Inc. $209.3M — (loss-making) — (loss-making) +10.44% (above 0%: growing) n/m +12.78% (above 0%: growing) 0.00% (25.42%) Compare
XGN Exagen Inc. $184.1M — (loss-making) — (loss-making) +15.92% (above 0%: growing) n/m +211.34% (above 0%: growing) 61.27% (8.64%) Compare
Median of peers $1.1B — — +11.44% — +12.42% 61.27% (20.10%)

All 49 Diagnostics & Research stocks →

Pay and ownership Proxy statement filed 14 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2024 13.63m 7.21m 69.00
2023 12.11m 14.20m 97.00
2022 11.39m (4.48m) 73.00
2021 12.79m 29.79m 140.00

Ownership

Directors and executive officers, together 1.90%
BlackRock, Inc. 8.40%
The Vanguard Group 8.30%
Millennium Management LLC 7.10%
State Street Corporation 6.30%
Glenview Capital Management 5.20%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Myriad Genetics, Inc. (MYGN) Latest News

5 Nov

Impact 4 · · The Motley Fool transcript
Impact 4 · · GuruFocus.com

4 Nov

Impact 3 · · Associated Press
Impact 3 · · MarketBeat transcript
Impact 3 · · StockStory
Impact 3 · · GlobeNewswire

22 Oct

Impact 4 · · Simply Wall St.
Impact 4 · · GlobeNewswire
Impact 3 · · medtechdive.com

21 Oct

Impact 4 · · StockStory

20 Oct

Impact 4 · · StockStory
Impact 4 · · Investing.com
Impact 4 · · GlobeNewswire

14 Oct

Impact 3 · · Simply Wall St.

8 Oct

Impact 4 · · PR Newswire
Impact 4 · · CNW Group
Impact 4 · · GlobeNewswire
Impact 4 · · PR Newswire

3 Oct

Impact 3 · · Simply Wall St.

2 Oct

Impact 3 · · StockStory

24 Sep

Impact 3 · · StockStory

18 Sep

Impact 3 ·

1 Sep

Impact 4 ·

3 Aug

Impact 3 ·

2 Aug

Impact 4 ·

31 Jul

Impact 3 · · MarketBeat transcript
Impact 3 · transcript

30 Jul

Impact 4 ·
Impact 3 ·

27 Jul

Impact 3 · · businessinsider.com
stockrow.com/MYGN · Data as of Nov 2, 2026 · For information only; not investment advice. · © 2026 stockrow.com